Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Signal Transduction >> Protein Phosphorylation >> Ser / Thr Phosphatases
Overview
Product name
Anti-FCP1 antibody
See all FCP1 products (5) ...
Description
Mouse polyclonal to FCP1
Tested applications
Cross reactivity
Reacts with
Human
Immunogen
Vector coding for a partial recombinant fusion protein, corresponding to internal sequence amino acids 301-400 of Human FCP1. Target sequence used to make the antibody: IDDRKDVWKF APNLITVKKY VYFQGTGDMN APPGSRESQT RKKVNHSRGT EVSEPSPPVR DPEGVTQAPG VEPSNGLEKP ARELNGSEAA TPRDSPRPGK.
IDDRKDVWKF APNLITVKKY VYFQGTGDMN APPGSRESQT RKKVNHSRGT EVSEPSPPVR DPEGVTQAPG VEPSNGLEKP ARELNGSEAA TPRDSPRPGK
Properties
Form
Liquid
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage buffer
Preservative: None
Constituents: 50% Glycerol, Whole serum.
Purity
Whole antiserum
Primary antibody notes
This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al.PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animal's cells produce the protein, which stimulates the animal's immune system to produce antibodies against that particular protein. A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein. Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.
Clonality
Polyclonal
Isotype
IgG
-
Western blot - FCP1 antibody (ab52722)
(enlarge)
Applications
Show applications key
Our Abpromise guarantee covers the use of ab52722 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
- 1 Image
WB
Application notes
WB: 1/1000. Predicted molecular weight: 104 kDa.
This antibody has been tested in Western blot against an E.coli lysate containing the partial recombinant fusion protein used as an immunogen. We have no data on detection of endogenous protein.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Target
Function
Processively dephosphorylates 'Ser-2' and 'Ser-5' of the heptad repeats YSPTSPS in the C-terminal domain of the largest RNA polymerase II subunit. This promotes the activity of RNA polymerase II.
Tissue specificity
Ubiquitously expressed. Isoform 3 is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and placenta.
Involvement in disease
Defects in CTDP1 are a cause of congenital cataracts facial dysmorphism and neuropathy syndrome (CCFDN) [MIM:604168]. CCFDN is an autosomal recessive developmental disorder that occurs in an endogamous group of Vlax Roma (Gypsies). The syndrome is characterized by a complex clinical phenotype with seemingly unrelated features involving multiple organs and systems. Developmental abnormalities include congenital cataracts and microcorneae, hypomyelination of the peripheral nervous system, impaired physical growth, delayed early motor and intellectual development, facial dysmorphism and hypogonadism. Central nervous system involvement, with cerebral and spinal cord atrophy, may be the result of disrupted development with superimposed degenerative changes. Affected individuals are prone to severe rhabdomyolysis after viral infections and to serious complications related to general anesthesia (such as pulmonary edema and epileptic seizures).
Sequence similarities
Contains 1 BRCT domain.
Contains 1 FCP1 homology domain.
Post-translational
modifications
Phosphorylated. In the presence of TFIIF, the phosphorylated form has an increased CTD phosphatase activity. The phosphorylation is required for the physical interaction with GTF2F1.
Cellular localization
Nucleus.
Target information above from: UniProt accessionQ9Y5B0
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Alternative names
- CCFDN antibody
- CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 antibody
- CTD of POLR2A, phosphatase of, subunit 1 antibody
see all
Database links
- Entrez Gene: 9150 Human
- Omim: 604168 Human
- SwissProt: Q9Y5B0 Human
- Unigene: 465490 Human
Anti-FCP1 antibody images:
Western blot - FCP1 antibody (ab52722)
All lanes : Anti-FCP1 antibody (ab52722) at 1/1000 dilution
Lane 1 : 20µg of a total protein extract from E coli with ~50ng to 500ng of a tagged fusion protein of an irrelevant antigen.
Lane 2 : 20µg of a total protein extract from E coli with ~50ng to 500ng of the antigen (Tagged fusion protein).
Secondary
Rabbit anti-mouse IgG + IgM, (H+L) HRP conjugated, at 1/5000 dilution
Predicted band size : 104 kDa
Observed band size : 38 kDa (why is the actual band size different from the predicted?)
The molecular weight of the band on the western blot does not correspond to the molecular weight of the natural protein because only a fragment of the gene is used and it is fused to enzyme tag.
References for Anti-FCP1 antibody (ab52722)
ab52722 has not yet been referenced specifically in any publications.
Publishing research using ab52722? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"